What is ICANS?

CAR-T Toxicities: CRS and ICANS

Treating CRS and ICANS: current approaches and future outlooks

Let’s Take a BiTE Out of CRS and Neurotoxicity - B. Kikani - 20231018

Immune Effector Cell Therapy in Hematologic Malignancies: Lessons Learned

Managing the side effects of CAR-T therapies

Managing Acute Toxicities of CAR T-cell Therapy

Updates in the management of CAR-T toxicities

GPRC5D-Targeted CAR T-Cell Therapy for RRMM: Phase 1 Study Outcomes of BMS-986393 (CC-95266)

Results from a Phase I/II trial of pirtobrutinib and LV20.19 for patients with R/R lymphomas

Module 2: Toxicity Assessment and Management | Early & Late Side Effects

CAR T-Cells Multiple Myeloma: Adam Sperling, MD, PhD

Cynthia Harrison, medical student, National Cancer Institute (NCI)

An update on the ELiPSE-1 study: safety data from patients treated with CNTY-101, a CAR-NK therapy

Cilta-cel Effective in Lenalidomide-refractory Multiple Myeloma

Impact of age and co-morbidities on axi-cel efficacy

Retrospective study of anakinra to manage ICANS in patients treated with CAR-T therapy

Evaluating the safety and efficacy of elranatamab in multiple myeloma

Immune-Cell Engineering with Mark Leick, MD

What are the strategies to manage toxicities with CAR T-cell therapies?